Hold UNH at 85-95% benchmark weight with pre-committed triggers and $352 structural backstop until Oct 13 Q3 catalyst
Three-analyst synthesis resolves to HOLD: Aggressive analyst correctly identifies $352 floor backed by $24.3B TTM FCF, A-rated balance sheet, and 16.24x forward P/E but incorrectly frames MACD as coiled spring; Conservative analyst correctly identifies MACD bearish non-divergence (September -7.01 vs August -7.20 at lower prices) and that 14% YTD gain means recovery is already partially priced in; Neutral synthesis captures symmetric risk-reward (~2:1 upside to first resistance vs 4-5% downside to floor) and validates 'HOLD means hold' discipline per 09-28 binding lesson that structural backstop has held nine prior cycles. Upside targets: $375.15 (+2.0%), $386.73 (+5.2%), $397.39 (+7.9%), $482 consensus (+30.5%). Downside: $352 (-4.2%), $349.61 weekly close exit (-4.8%), $300 bear intermediate (-18.4%), $256 deep bear (-30.5%). Catalyst watchlist: commercial MLR normalization to 11%, FY26 EPS guide ($19.50-20.00), Medicaid margins, Optum Health goodwill, PBM regulatory developments.
| Position | Action |
|---|---|
| Default position | 85-95% of benchmark weight |
| 3-5 day window expires without resolution | Trim to lighter Underweight (~10-15% reduction) at spot per 09-29 binding lesson |
| Buy triggers hit | Scale in per 25-33% per session framework without deviation |
| Lower-Bollinger tag entries | Avoid - these are momentum signals, not reversal signals |
UNH is a compelling buying opportunity at $367.08, trading at 16.2x forward P/E with a 5x earnings inflection underway, oversold technicals at a rising 200 SMA, and an operational rebuild underway with new leadership—presenting asymmetric upside into Q3 2026 earnings.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $375.15 | bearish |
| 50 SMA | $394.27 | bearish |
| 200 SMA | $352.22 | neutral |
| RSI (14) | 34.43 | bearish |
| MACD | –6.27 | bearish |
| MACD Signal | –6.19 | bearish |
| MACD Histogram | –0.08 | bearish |
| Bollinger Upper | $400.45 | neutral |
| Bollinger Middle | $381.11 | neutral |
| Bollinger Lower | $361.77 | neutral |
| ATR | $8.63 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Flush to $352 that holds on weekly close with constructive MACD turn
Then: Pre-committed buy trigger - scale in 25-33% per session
Earnings inflecting dramatically from Q4 2025 trough
↩ rebuts: “Bear's 'three years of shrinking operating margins' thesis is outdated history”
EV: ~60% total return potential (targets ~$482-$600) · concedes: 200 SMA at $352 is only ~$15 away from current price $367.08; Momentum is poor with MACD re-accelerating lower; Price broken below two-week base of $374-$378; Trend has been falling for three months
UNH is a falling knife trading at 16.2x forward P/E with broken technicals, overstated earnings inflection, and no clear asymmetry to the upside—the stock is priced for a normal recovery that may not materialize given regulatory scrutiny, operational headwinds, and hostile macro conditions.
EV: EV calculation at $367.08: Bullish scenarios (35% × $387 + 20% × $461) = $227.7; Bearish scenarios (35% × $320 + 10% × $267) = $138.7; Combined EV ≈ $366.4 ≈ current price, indicating no asymmetry to upside. Scenario breakdown: | Scenario | Price Target | Probability | |---|---|---| | Q3 in-line/mild beat, prior-auth optics fade, technical bounce | $380–$394 | 35% | | Q3 disappoints, 200 SMA breaks | $300–$340 | 35% | | Q3 strong beat, leadership reset delivers | $440–$482 | 20% | | Q3 catastrophic miss, MLR spike, regulatory action | $255–$280 | 10% | · concedes: Q3 strong beat combined with leadership reset delivering could push toward $440-$482 (street target); A technical bounce to $380-$394 on in-line Q3 results and prior-auth optics is plausible; The stock could be in 'oversold in a downtrend' territory; Trefis data showing 'three consecutive years of shrinking operating margins' was not directly refuted, only dismissed; Some H1 2026 strength is genuine (the 2x improvement vs H1 2025 is real, even if not the marketed 5x)
→ vs conservative: Backward-looking trailing P/E of 23.59 reflects trough earnings ($0.01 Q4 2025) while ignoring forward P/E of 16.24 and 5x earnings inflection; technical damage narrative overstates September 30th breakdown when volume (4.78M) was non-climactic and RSI was already stretched at 34.43
→ vs neutral: EV calculation anchors to current margins rather than structural 9-10% operating margin recovery; DCF models systematically underestimate equity story given $24.3B TTM free cash flow and active deleveraging
| neutral |
| Close | $367.08 | bearish |
| Open | $374.93 | neutral |
| High | $374.05 | neutral |
| Low | $365.76 | neutral |
| Volume | 4.78M | neutral |
Support: 365.76 · 361.77 · 352.22 | Resistance: 375.15 · 381.11 · 394.27 · 400.45
UNH closed at $367.08 on 2026-09-30, breaking below the recent $374–$378 range floor on a bearish outside day with 4.78M volume. All short- and medium-term trend indicators are bearish: price below the 10 EMA ($375.15) and 50 SMA ($394.27), with the 50 SMA falling since 8/17 and the 10 EMA declining since 7/24. The 200 SMA ($352.22) remains the critical long-term support line and is still rising, confirming the secular uptrend is intact but at risk. Momentum is firmly negative with MACD at –6.27 (below signal at –6.19 and just flipped histogram negative at –0.08), and RSI at 34.43 is in oversold territory without a confirmed bullish divergence. The composite technical reading is BEARISH with oversold extremes, recommending hold-or-defend for existing longs with the 200 SMA as the trailing stop discipline, while swing traders should wait for confirmation before initiating new positions.
Market Cap
$329.49B
Share Price
~$364
Beta
0.62
P/E (TTM)
23.59
Forward P/E
16.24
PEG Ratio
1.02
P/B
3.37
Dividend Yield
2.48%
EPS (TTM)
$15.56
Forward EPS
$22.61
Revenue (TTM)
$450.5B
Gross Profit (TTM)
$88.86B
EBITDA (TTM)
$26.68B
Net Income (TTM)
$14.12B
Operating Margin
7.13%
Profit Margin
3.14%
Return on Equity
14.15%
Return on Assets
4.87%
Total Assets
$309,727M
Total Debt
$73,328M
Net Debt
$44,743M
Net Debt / EBITDA
~1.7x
Goodwill + Intangibles
$130,394M
Tangible Book Value
($31,947M)
Free Cash Flow (TTM)
$24.3B
Q2 2026 Revenue
$112,032M
Q2 2026 Gross Profit
$23,299M
Q2 2026 Operating Income
$7,991M
Q2 2026 Net Income
$5,484M
Q2 2026 Diluted EPS
$6.04
Q2 2026 EBITDA
$8,970M
Q2 2026 Operating Cash Flow
$11,052M
Q2 2026 Free Cash Flow
$10,253M
Q2 2026 Cash Dividends Paid
$2,087M
Q2 2026 Net Debt Repayment
$4,413M
H1 2026 Diluted EPS
~$12.94
H1 2026 Net Income
~$11.76B
H2 2025 Net Income
~$2.36B
Dividend Run Rate
~$8B/yr
Q4 2025 Net Income
$10M
Q4 2025 Diluted EPS
$0.01
Strengths
Concerns
HOLD
Macro: Long-end Treasury yields are the dominant macro theme: 30-year at highest since 2002, mortgage rates at 7.58% (near 3-year high), with Moody's Zandi warning of economic damage. Fed is aggressively hawkish per prediction markets (97% probability of no cuts in 2026, possible October hike). US recession odds at 8% (+1pp wk/wk) — low but drifting higher. Defensive dividend payers like UNH attract flows during rate-driven risk-off, but the discount rate on long-duration earnings is rising. Healthcare sector has been a relative outperform (+46.9% over 6 months, +25.5pp vs S&P 500), providing a sector tailwind.